^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GEN0101

i
Other names: GEN0101, TSD-0014, HVJ-E, GEN 0101
Associations
Company:
AnGes MG, TSD Japan
Drug class:
Immunostimulant
Related drugs:
Associations
almost3years
A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma. (PubMed, Cancer Immunol Immunother)
The activity of NK cells and interferon-γ levels were increased in the circulation, indicating augmentation of antitumor immunity by GEN0101. This trial showed not only the safety and tolerability but also the significant antitumor effect of GEN0101, suggesting that GEN0101 might be a promising new drug for patients with advanced melanoma.
Clinical • P1 data • Journal
|
IFNG (Interferon, gamma)
|
GEN0101
over4years
Intratumoral and subcutaneous injection of HVJ-E (GEN0101) in metastatic castration-resistant prostate cancer. (PubMed, Cancer Sci)
In conclusions, intratumoral and subcutaneous injections of GEN0101 were well tolerated and feasible to use. The study is registered at UMIN Clinical Trials Registry, number UMIN000017092.
Journal
|
KLK3 (Kallikrein-related peptidase 3)
|
GEN0101